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Abstract
Objective: To report the case of two siblings with chronic granulomatous disease. Chronic granulomatous
disease is a primary immunodeficiency disorder characterized by abnormal microbicidal activity. Mutations in the
p47-phox gene (NCF-1) are present in about 30% of the patients with chronic granulomatous disease; this group
presents a better prognosis and later onset of recurrent infections as compared with the X-linked variant, present
in about 56% of patients.
Description: Case 1 is a female presenting repeat infections since age 10, starting with impetigo followed by
severe pneumonia six months later. The severity of the lung infection associated with liver abscess and the patients
resistance to treatment prompted laboratory investigation for immunodeficiency. The results of the nitroblue
tetrazolium and superoxide release tests were consistent with a diagnosis of chronic granulomatous disease. The
parents and siblings were assessed, revealing the presence of granulomatous disease in a brother (Case 2). He also
presented repeat infections with impetigo at age 10, followed by pneumonia six months later, however in a non
severe form. Single-strand conformational polymorphism analysis detected abnormal electrophoretic mobility of
exon 2 of the NCF-1 gene. Sequence DNA analysis revealed a dinucleotide GT deletion in exon 2.
Comments: It is important to evaluate the relatives of chronic granulomatous disease patients, even in the
absence of typical clinical signs. Defining the mutation and its correlation with phenotype is important to provide
appropriate genetic counseling and clinical prognosis.
J Pediatr (Rio J). 2004;80(5):425-8: Chronic granulomatous disease, immunodeficiency, NADPH oxidase,
p47-phox.
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CASE REPORT
Introduction
Chronic granulomatous disease (CGD) is a syndrome
characterized by genetic abnormalities which result in
defective production of oxygen reactive species, interfering
in the capacity of leukocytes to destroy microorganisms.1
The incidence of CGD is approximately 1 in 250,000
live births.2
A genetic abnormality at the gp91-phox, p22-phox,
p47-phox or p67-phox proteins that are part of the NADPH
oxidase system can result in an expression and/or function
failure of this electron transport system, leading to the
CGD phenotype.3
The most common form of CGD is caused by a defect in
gp91-phox, which has X-linked inheritance (X-CGD, 56%),
followed by the autosomal recessive forms resulting from an
alteration to p47-phox (A47-CGD, 30%), p22-phox (A22-
CGD, 5 to 7%) and p67-phox (A67-CGD, 5 to 7%).2
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Clinically CGD is characterized by repeated catalase-
positive microorganism infections, primarily Staphylococcus
aureus, gram-negative bacteria and Aspergillus, in addition
to intracellular microorganisms, such as Pneumocystis carinii
and Mycobacterium spp, which frequently affect the skin,
lungs, liver, spleen, lymph nodes and bones.2 Inflammatory
granulomas can form in the gastrointestinal tract and
urinary system, causing obstructive symptoms in the
esophagus, stomach or duodenum,4 in addition to
manifestations similar to intestinal inflammatory disease.5
Patients with X-linked heredity present earlier
manifestations, during the first year of life, and diagnosis is
generally made before 2 years.2,6 Additionally, infections
tend to be more serious and the number of hospitalizations
is greater than for patients with recessive autosomal
heredity.2,6
According to the Pan American Primary Immunodeficiency
Study Group (PAGID - Grupo Pan-Americano de Estudo em
ImunodeficiŒncias PrimÆrias),CGD diagnosis is made for
males or females based on the nitroblue tetrazolium (NBT)
test or the presence of altered phagocyte respiratory burst
(less than 5% of the controls) and who present: gp91-phox,
p22-phox, p47-phox or p67-phox mutations or absent
mRNA observed by Northern blot analysis for one of the
genes listed or mother, cousins, uncles or nephews with
abnormal NBT results or respiratory burst.7
The NBT test on slides is an extremely useful method for
CGD diagnosis, and also allows carriers of the defect
(mothers, sisters) in X-CDG cases.8
This study presents a clinical, biochemical and molecular
analysis of two siblings with autosomal recessive CGD due
to a p47-phox defect.
reactions and presented adequate pondero-statural and
neuropsychomotor development.
In June 1992, at 10 years of age, presented with
pneumonia treated over two fifteen-day periods with
ampicillin, followed by 45 days on a triple regime for
tuberculosis, without improvement. She was then given
cephalothin and chloramphenicol, progressing with a discrete
clinical and radiological improvement. The pulmonary biopsy
performed at this stage of the treatment found non-specific
inflammation with lymphohistiocytic infiltration and the
presence of multi-nucleus giant-cell granulocytes and fibrosis
encirclement; the culture taken from this material was
negative for fungi and bacteria. Broncho-alveolar lavage
cultures were positive for Candida sp and Streptococcus
pneumoniae.
The patient progressed with chronic lung disease and
required renewed hospitalization in February, to treat
pneumonia and liver abscess, and April 1993. It was at this
point that the diagnosis of CGD was established by NBT
reduction in granulocytes stimulated with phorbol myristate
acetate (PMA) (1 µg/ml) of < 5% that of the control and the
patients mother. Similarly, superoxide anion production in
response to PMA stimulus (30nM) in the presence of
cytochrome C (80 µM) was very low in comparison with the
healthy control and the mother (Table 1).
She was discharged from her last hospitalization on
ciprofloxacin and human recombinant gamma interferon
exhibiting a moderate level of control over the lung infections.
The following year, the gamma interferon was withdrawn
and since then she has been using sulfamethoxazole and
trimethoprim irregularly. She progresses with significant
improvements in the lung condition with normal pulmonary
function. Over the 9-year follow-up period, she presented
bartholinitis (1999) and a case of single pneumonia (2003),
both treated with success in outpatients.
Case 2 (II.3 - Adm.O.M., male)
In common with his sister, the patient received full basic
immunization with no adverse reactions and always exhibited
adequate pondero-statural and neuropsychomotor
development.
Presented three episodes of impetigo affecting the
axillary region bilaterally and the lower limbs, in 2000. In
January of 2001, presented pneumonia which was treated
for 10 days with sulfamethoxazole and trimethoprim.
Table 1 - Superoxide anion level of patients with CGD
* Spontaneous release of superoxide anion by polymorphonuclear cells.
† Release of superoxide anion by polymorphonuclear cells stimulated with phorbol myristate acetate
(PMA).
‡ Spontaneous release of superoxide anion by mononuclear cells.
§ Release of superoxide anion by mononuclear cells stimulated with PMA.
Patient Spo PMN* PMN PMA Spo MONO  MONO PMA§
Adr.O.M. 1.0 1.03 -1.33 0.37
Ade.O.M. -0.01 1.94 0.37 0.37




Case 1 (II.2 - Adr.O.M., female)
The second daughter of non-consanguineous parents.
Received complete basic immunization with no adverse
Description of the cases
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Between August and December of 2001, presented two
further episodes of impetigo, responding adequately to
antibiotic treatment.
The elder brother of these two patients and also their
mother and father are asymptomatic.
Disease presentation in both sexes was suggestive of
CGD with recessive autosomal heredity, i.e. abnormalities
in protein p47, p67 or p22-phox. Of all these CGD variants,
that which exhibits the most favorable clinical outcome, as
exhibited by the patients described here, is A47-CGD. In
order to determine whether this was indeed a case of
abnormal NADPH oxidase system behavior, a single-strand
conformational polymorphism (SSCP) analysis was initially
performed for the p47-phox chain. This method allows
mutations to be detected by means of a three-dimensional
view of the DNA structure. In the knowledge that the great
majority of patients with A47-CGD present a homozygous
deletion of GT nucleotides at the start of exon 2 of the NCF-
1 gene (GenBank access number: NM 000265), polymerase
chain reaction (PCR) was performed with the oligonucleotide
48F-451R. In order to do this we used genomic DNA (gDNA)
in PCR, which is subjected to electrophoresis under denaturing
conditions. A migratory pattern was observed in both
patients that was distinct from the patterns observed in two
healthy individuals (Figure 1).
This specific DNA region was then sequenced using a
commercially available kit (DNA sequencing Kit, Big Dye
Terminator Cycle Sequencing Ready Reaction for ABI 377
PE/Applied Biosystems), as previously published, confirming
that both patients exhibited the GT (∆GT) deletion at the
start of exon 2 (Figure 2).
Comments
Abnormal NADPH oxidase activity, characteristic of CGD,
results in an important deficiency that involves the initial
stage of the defense against infections. Since there is a
great deal of contact between external agents and the skin
and respiratory and gastrointestinal mucosa, the organisms
natural barriers, these areas, together with adjoining tissues,
are the primary targets of microbial invasion and are
frequently the site of infectious processes in CGD patients.2,9
Both patients in this study exhibited late-onset infections,
and only Adr.O.M. presented severe infection. Other than
skin and lung infections and liver abscess, they did not
present other frequent CGD-linked infectious conditions,
such as abscesses of soft tissues, suppurating adenitis and
osteomyelitis.
Pulmonary infections constitute the most common form
of invasive infection in CGD,2 and pulmonary involvement is
associated with a significant increase in morbidity and
mortality, since repeated pneumonia can progress to
bronchiectasis and pulmonary fibrosis.
While the topography of the infectious processes was
suggestive of a phagocyte-related immunodeficiency, the
favorable clinical progress contrasts with descriptions of
CGD patients.10 Recently, a sample of 368 patients described
by Winkelstein et al. demonstrated earlier onset of symptoms
Figure 1 - Single-strand conformational polymorphism of pati-
ents with CGD: migratory pattern of exon 2 of the
NCF-1 gene. Note the abnormal migratory pattern in
the patients (Adr, Ade) if compared to normal sub-
jects (N). In the autosomal recessive genetic pat-
tern, the mutation presents a homozygous form,
and, therefore, in the electrophoretic mobility, both
DNA bands overlay each other (Adr, Ade)
Figure 2 - Genomic DNA sequencing of patients with CGD and
contol: analysis of the sequence of the exon 2 of the
NCF-1 gene. A: Patient Adr. Note a deletion of the GT
nucleotide (∆GT) at the start of the exon 2. B:
Patient Ade. Note the same ∆GT mutation in the base
of the exon 2. C: Control, note the double sequence
of the NCF-1 gene (upper sequence) with the pre-
sence of the pseudogene (lower sequence), and the
G bases (black) and T bases (red) are highlighted,
which are not present in Figures 2A and 2B
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and greater mortality rate among patients with X-linked
CGD (p < 0.02).2 Furthermore, a greater prevalence of
inflammatory manifestations was observed, causing gastric
and urinary obstructions, and also of certain types of
infection (perirrectal abscesses, suppurating adenitis and
septicemia) among the patients with X-CDG.2
According to some authors, the more favorable outcomes
observed with A47-CGD may be attributable to a residual
level of hydrogen peroxide and superoxide production by
neutrophils deficient in p47-phox.11 We, however, observed
extremely low levels in the patients described here, similar
to the levels seen in Brazilian patients with X-CGD.12
Another important characteristic of A47-CGD is the
fact that the same NCF-1 mutation is found in different
families, in contrast with X-CGD for which 300 mutations
have been described, 200 of which were exclusive to each
family.13 Among the 82 patients with p47-phox
abnormalities who had been studied by the year 2000, 74
presented the same mutation, a homozygous deletion of
the GT nucleotide, corresponding to the first four bases of
the second exon of the NCF-1 gene. The remaining
patients were either heterozygotes for the GT deletion
(n = 6) or presented some other mutation in association
with the GT deletion (n = 2).14 The elevated frequency of
the GT deletion at the start of exon 2 of the NCF-1 gene
in unrelated patients, impacting on p47-phox, is explained
by the existence of a highly homologous pseudogene,
which, by means of meiotic recombination phenomena
which result in the normal gene being eliminated or
corrupted.15 Two new mutations to the NCF-1 gene were
identified recently: one is a G579A homozygous mutation,
forming a stop codon, with the patients parents being
heterozygotes for the mutation, and the second case is a
heterozygous G579A mutation.16
Studies that describe the interrelated clinical and
molecular aspects of CGD are important to establish
prognosis, adequate genetic counseling and possible future
therapy.
Testing for CGD in relatives of patients who have been
diagnosed should be considered even when these relatives
do not exhibit characteristic clinical signs and symptoms.
It is possible that the autosomal recessive forms of CGD
may occur with greater frequency than is currently
observed, if they were to be researched more often and
in greater depth.
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